MedTrace Logo

Is There a Sensibility Increased in the Growth Hormone at Child With Prader-Willi Syndrome?

NCT01298180 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 111

Last updated 2021-09-24

No results posted yet for this study

Summary

The purpose of this study is to estimate the sensibility at the growth hormone in vivo at the children presenting a Prader-Willi syndrome (SPW) in comparison with children presenting a deficit in growth hormone (GHD).

Conditions

Interventions

DRUG

Growth hormone (Genotonorm® or Omnitrope®)

drug : the treatment will be begun in progressive dose by beginning by ¼ of the dose the first week, then ½ of the dose the second week, then 3/4 of the dose the third week and total dose the fourth week.

PROCEDURE

DEXA, blood tests, H.G.P.O, osseous age.

SPW, GHD, SPW-B : blood tests : centralized dosage H.G.P.O : adjusted to children's age.

PROCEDURE

biopsy

Biopsy : Cutaneous and fat tissue biopsy.

Sponsors & Collaborators

  • University Hospital, Toulouse

    lead OTHER

Principal Investigators

  • Maithé TAUBER, MD · University Hospital, Toulouse

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
1 Year
Max Age
5 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-01-31
Primary Completion
2013-05-31
Completion
2013-05-31

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01298180 on ClinicalTrials.gov